Mark Kester headshot
MK

Mark Kester

Professor
Unit: School of Medicine
Department: Department of Pharmacology
Office location and address
1340 Jefferson Park Ave
Charlottesville, Virginia 22903
Education
PhD, State University of New York at Buffalo
Postdoc, University of Illinois, Chicago
Targeted Sphingolipid Metabolism for Treatment of AML
Source: U.S. NIH Cancer Institute
June 01, 2020 – May 31, 2025
PharmaScience project
Source: Pharmascience Inc.
September 02, 2019 – September 01, 2021
Transfoam - A synthetic biology platform for Biodegradable Plastic Formation
Source: VentureWell
December 01, 2020 – August 31, 2021
Fellowship on behalf of Pedro Filipe da Costa Pinheiro - Ceramide NanoLiposomes as a novel therapeutic for prostate cancer
Source: National Cancer Institute, NIH
September 10, 2019 – August 31, 2021
Nanoscale natural products for the treatment of AML
Source: Case Western Reserve University
September 01, 2020 – August 31, 2021
Ceramide Nanoliposomes in Combination with Focused Ultrasound for Treating Breast Cancer
Source: U.S. NIH Cancer Institute
August 01, 2018 – July 31, 2021
Combination of ceramide and immunotherapy in treatment of hepatocellular cancer
Source: CURATORS OF THE UNIVERSITY OF MISSOURI
July 01, 2017 – June 30, 2021
AgroSpheres-Enabled Biological Fungicide
Source: Virginia Polytechnic Institute and State Universit
May 01, 2019 – November 30, 2020
Generating Nanoparticles of Romidepsin for the Treatment of Cancers
Source: The Trustees of Columbia University in the City of
February 12, 2019 – February 11, 2020
Nano-Enhanced Vaccine for Melanoma
Source: Center For Innovative Technology
July 01, 2018 – December 31, 2019
SEM Imaging of hydrogel electrochemical sensing layer of microchip ISF detectors
Source: Cambridge Medical Technologies
October 01, 2017 – September 30, 2019
MD-INMD-HO Targeted Sphingolipid Metabolism for Treatment of AML
Source: U.S. NIH Cancer Institute
September 18, 2015 – August 31, 2019
Characterization of Small Nanoparticles
Source: Bonumose LLC
May 09, 2019 – May 31, 2019
EN-MATSCI Targeting drug-eluting nanoparticles to tumor-associated macrophages for cancer immunotherapy
Source: La Jolla Institute for Allergy & Immunology
November 15, 2016 – November 01, 2018
VentureWell E. Team Grant 2016
Source: VentureWell
July 01, 2016 – June 30, 2018
MD-PHAR Novel Nanoparticle Therapy for Pancreatic Cancer
Source: Pennsylvania State University
March 01, 2016 – February 28, 2018
MD-PHAR Insulin-ORAL Renewal Application
Source: Center For Innovative Technology
July 01, 2015 – June 30, 2016
MD-PHAR Novel Nanoparticle Therapy for Pancreatic Cancer YR2
Source: Pennsylvania State University
March 01, 2015 – February 29, 2016
MD-PHAR Targeted siRNA Nanojackets for Personalized Breast Cancer Therapy
Source: Keystone Nano, Inc.
October 01, 2014 – February 29, 2016
Cancer Center Support Grant - Year 21
Source: U.S. NIH Cancer Institute
June 05, 2012 – January 31, 2016
MD-INMD Targeted Sphingolipid Metabolism for Treatment of AML
Source: Pennsylvania State University
September 01, 2014 – August 31, 2015
MD-PHAR A pH-resistant Nanoparticle Platform for Oral Delivery of Insulin
Source: Center For Innovative Technology
July 01, 2014 – June 30, 2015
MD-PHAR Novel Nanoparticle Therapy for Pancreatic Cancer
Source: Pennsylvania State University
March 01, 2014 – February 28, 2015
MD-INMD Targeting Acid Ceramidase in AML
Source: Pennsylvania State University
September 10, 2013 – August 31, 2014
ENGR 2595: Special Topics in Engineering
Credits: 1–4
Special Topics in Engineering.
ENGR 4595: Special Topics in Engineering
Credits: 1–3
Advance projects course to be taken in parallel with STS 4010, 4020, or can be used for an advanced undergraduate course on a topic not covered in the course offerings. Prerequisite: instructor permission.
ENGR 4599: Special Topics in Engineering
Credits: 1–3
Prerequisite: instructor permission.
PATH 9995: Topical Research
Credits: 1–12
Original research on approved problems.
PATH 9999: Non-Topical Research
Credits: 1–12
Dissertation research credit for students who have completed their advancement to candidacy.
AgroSpheres, Chief Scientific Officer
http://www.agrospheres.com/